| Helicobacter pylori-related gastroenterology studies | Lifetime | 10 | IT 1 | 99.92 |
| Celiac Disease Research and Management | Lifetime | 6 | IT 1 | 99.68 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 14 | IT 1 | 99.77 |
| Gut microbiota and health | Lifetime | 27 | IT 1 | 99.87 |
| Digestive system and related health | Lifetime | 14 | IT 1 | 99.49 |
| Eosinophilic Esophagitis | Lifetime | 26 | IT 1 | 99.76 |
| Gastrointestinal disorders and treatments | Lifetime | 35 | IT 1 | 99.76 |
| Gastrointestinal motility and disorders | Lifetime | 22 | IT 1 | 99.74 |
| Liver Disease Diagnosis and Treatment | Lifetime | 148 | IT 9 | 99.76 |
| Microscopic Colitis | Lifetime | 42 | IT 2 | 99.66 |
| Diet and metabolism studies | Lifetime | 174 | IT 3 | 99.57 |
| Galectins and Cancer Biology | Lifetime | 40 | IT 2 | 99.16 |
| Liver Disease and Transplantation | Lifetime | 168 | IT 14 | 99.44 |
| Gastroesophageal reflux and treatments | Lifetime | 92 | IT 5 | 99.28 |
| Inflammatory Bowel Disease | Lifetime | 166 | IT 11 | 99.12 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 272 | IT 27 | 99.00 |
| COVID-19 Clinical Research Studies | Lifetime | 448 | IT 56 | 98.22 |
| Liver physiology and pathology | Lifetime | 157 | IT 12 | 98.45 |
| Gastric Cancer Management and Outcomes | Lifetime | 676 | IT 40 | 98.62 |
| Veterinary medicine and infectious diseases | Lifetime | 80 | IT 5 | 98.05 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 450 | IT 24 | 98.61 |
| Hepatitis C virus research | Lifetime | 671 | IT 56 | 98.24 |
| Nutrition and Health in Aging | Lifetime | 616 | IT 41 | 97.84 |
| Alcohol Consumption and Health Effects | Lifetime | 333 | IT 20 | 97.49 |
| COVID-19 and healthcare impacts | Lifetime | 480 | IT 57 | 94.62 |
| Diet, Metabolism, and Disease | Lifetime | 578 | IT 41 | 97.31 |
| Long-Term Effects of COVID-19 | Lifetime | 760 | IT 124 | 95.12 |
| Pancreatitis Pathology and Treatment | Lifetime | 724 | IT 54 | 97.13 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 523 | IT 10 | 96.38 |
| Probiotics and Fermented Foods | Lifetime | 956 | IT 74 | 96.73 |
| Clinical Nutrition and Gastroenterology | Lifetime | 582 | IT 20 | 96.21 |
| Alcoholism and Thiamine Deficiency | Lifetime | 199 | IT 8 | 94.97 |
| Cancer Mechanisms and Therapy | Lifetime | 620 | IT 26 | 94.21 |
| Microbial Metabolites in Food Biotechnology | Lifetime | 950 | IT 35 | 95.64 |
| Autoimmune Bullous Skin Diseases | Lifetime | 784 | IT 54 | 95.06 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 387 | IT 25 | 94.50 |
| Liver Diseases and Immunity | Lifetime | 721 | IT 54 | 94.84 |
| Urticaria and Related Conditions | Lifetime | 913 | IT 64 | 93.60 |
| IL-33, ST2, and ILC Pathways | Lifetime | 934 | IT 43 | 92.46 |
| Whipple's Disease and Interleukins | Lifetime | 93 | IT 8 | 90.57 |
| Congenital gastrointestinal and neural anomalies | Lifetime | 440 | IT 21 | 91.45 |
| Biosimilars and Bioanalytical Methods | Lifetime | 988 | IT 46 | 88.54 |
| Hydrogen's biological and therapeutic effects | Lifetime | 673 | IT 36 | 75.93 |
| Pathogenesis and Treatment of Hiccups | Lifetime | 809 | IT 29 | 52.66 |
| Gut microbiota and health | 2021-2025 | 39 | IT 3 | 99.51 |
| Diet and metabolism studies | 2021-2025 | 92 | IT 13 | 98.72 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 28 | IT 5 | 97.77 |
| Gastrointestinal motility and disorders | 2021-2025 | 31 | IT 4 | 98.15 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 320 | IT 30 | 98.41 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 75 | IT 5 | 97.23 |
| COVID-19 Clinical Research Studies | 2021-2025 | 750 | IT 80 | 96.85 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 242 | IT 32 | 97.21 |
| Inflammatory Bowel Disease | 2021-2025 | 269 | IT 27 | 96.80 |
| Liver Disease and Transplantation | 2021-2025 | 312 | IT 38 | 96.88 |
| Long-Term Effects of COVID-19 | 2021-2025 | 756 | IT 102 | 94.19 |
| Clinical Nutrition and Gastroenterology | 2021-2025 | 105 | IT 8 | 93.92 |
| Nutrition and Health in Aging | 2021-2025 | 553 | IT 52 | 94.16 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 856 | IT 105 | 94.61 |
| Microscopic Colitis | 2021-2025 | 333 | IT 38 | 94.64 |
| Gastroesophageal reflux and treatments | 2021-2025 | 316 | IT 35 | 89.75 |
| Hepatitis C virus research | 2021-2025 | 721 | IT 53 | 90.05 |
| Gastrointestinal disorders and treatments | 2021-2025 | 548 | IT 55 | 86.66 |
| Eosinophilic Esophagitis | 2021-2025 | 616 | IT 88 | 88.02 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 681 | IT 72 | 86.37 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 530 | IT 27 | 81.56 |
| Appendicitis Diagnosis and Management | 2021-2025 | 700 | IT 92 | 77.02 |
| Liver Diseases and Immunity | 2021-2025 | 692 | IT 62 | 81.00 |
| Veterinary medicine and infectious diseases | 2021-2025 | 152 | IT 11 | 77.29 |
| Cancer Mechanisms and Therapy | 2021-2025 | 651 | IT 30 | 76.78 |
| Celiac Disease Research and Management | 2021-2025 | 456 | IT 91 | 76.28 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 910 | IT 56 | 74.59 |
| Liver physiology and pathology | 2021-2025 | 657 | IT 27 | 72.52 |
| Enhanced Recovery After Surgery | 2021-2025 | 871 | IT 72 | 66.23 |
| Nosocomial Infections in ICU | 2021-2025 | 974 | IT 95 | 66.90 |
| Digestive system and related health | 2021-2025 | 664 | IT 61 | 65.30 |
| Infant Health and Development | 2021-2025 | 600 | IT 50 | 63.83 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 802 | IT 73 | 61.65 |
| Intestinal and Peritoneal Adhesions | 2021-2025 | 658 | IT 50 | 57.16 |
